Andrew D. Moin's most recent trade in SAB Biotherapeutics Inc was a trade of 1,740,000 Common Stock done at an average price of $1.8 . Disclosure was reported to the exchange on Sept. 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics Inc | Andrew D. Moin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.75 per share. | 29 Sep 2025 | 1,740,000 | 2,198,457 | - | 1.8 | 3,045,000 | Common Stock |
| SAB Biotherapeutics Inc | Andrew D. Moin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Sep 2025 | 17,400 | 211,100 | - | - | Series B Convertible Preferred Stock | |
| SAB Biotherapeutics Inc | Andrew D. Moin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 228,500 | 228,500 | - | - | Series B Convertible Preferred Stock | |
| SAB Biotherapeutics Inc | Andrew D. Moin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 228,500 | 228,500 | - | - | Warrants (right to buy) | |
| SAB Biotherapeutics Inc | Andrew D. Moin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 114,250 | 114,250 | - | - | Warrants (right to buy) |